Guardant Health, Inc.

Equities

GH

US40131M1099

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-17 pm EDT			5-day change	1st Jan Change
16.39 ^USD	+1.42%		-14.23%	-39.41%

Apr. 15	Goldman Sachs Adjusts Guardant Health Price Target to $28 From $32, Maintains Buy Rating	MT
Apr. 03	Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting	CI

Guardant Health, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022

November 03, 2022 at 05:13 pm EDT

Guardant Health, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported revenue was USD 117.4 million compared to USD 94.78 million a year ago. Net loss was USD 161.99 million compared to USD 107.53 million a year ago. Basic loss per share from continuing operations was USD 1.58 compared to USD 1.06 a year ago.
For the nine months, revenue was USD 322.65 million compared to USD 265.55 million a year ago. Net loss was USD 514.65 million compared to USD 314.76 million a year ago. Basic loss per share from continuing operations was USD 5.04 compared to USD 3.11 a year ago.

Latest news about Guardant Health, Inc.

Goldman Sachs Adjusts Guardant Health Price Target to $28 From $32, Maintains Buy Rating	Apr. 15	MT
Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting	Apr. 03	CI
Guardant Health, Inc. Announces Results from the ECLIPSE Study Showing the Effectiveness of Its Shield Blood Test for Detecting Colorectal Cancer	Mar. 13	CI
Transcript : Guardant Health, Inc. Presents at Citi?s 2024 Unplugged Medtech and Life Sciences Access Day, Feb-29-2024 01:00 PM	Feb. 29
Piper Sandler Cuts Price Target on Guardant Health to $30 From $40, Maintains Overweight Rating	Feb. 26	MT
UBS Adjusts Guardant Health Price Target to $32 From $45, Maintains Buy Rating	Feb. 23	MT
Canaccord Genuity Adjusts Price Target on Guardant Health to $45 From $50, Maintains Buy Rating	Feb. 23	MT
Guardant Health Q4 Adjusted Loss Narrows as Revenue Rises	Feb. 23	MT
Transcript : Guardant Health, Inc., Q4 2023 Earnings Call, Feb 22, 2024	Feb. 22
Earnings Flash (GH) GUARDANT HEALTH Posts Q4 Revenue $155.1M, vs. Street Est of $150.8M	Feb. 22	MT
Guardant Health, Inc. Provides Earnings Guidance for the Year 2024	Feb. 22	CI
Guardant Health, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22	CI
Guardant Health, Inc. Announces Resignation of Mr. Samir Kaul as Member of the Board and as Member of the Compensation Committee of the Board	Feb. 01	CI
Goldman Sachs Cuts Price Target on Guardant Health to $37 From $43, Maintains Buy Rating	Jan. 29	MT
Transcript : Guardant Health, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 03:45 PM	Jan. 08
Guardant Health Reports Preliminary Q4 Revenue	Jan. 08	MT
EDX Medical maintains confident outlook; implements biopsy tests	Jan. 08	AN
Guardant Health Teams Up With Hikma Pharmaceuticals to Offer Cancer Diagnostics in Middle East, North Africa	Jan. 08	MT
Guardant Health Names Terilyn Juarez Monroe as Chief People Officer	Jan. 02	MT
Guardant Health, Inc. Announces Executive Changes	Jan. 02	CI
Sector Update: Health Care Stocks Mixed Pre-Bell Wednesday	Dec. 20	MT
Guardant Health Reports Tentative Date for US FDA Advisory Panel Review of Shield Blood Test	Dec. 19	MT
Guardant Health, Inc. Announces Tentative Date of FDA Advisory Panel Review of Shield(TM) Blood Test	Dec. 19	CI
Guardant Health Insider Sold Shares Worth $152,954, According to a Recent SEC Filing	Dec. 05	MT
Cancer Research UK and Guardant Health Launch Collaboration to Advance Cancer Research and Clinical Development Activities	Dec. 04	CI

Chart Guardant Health, Inc.

Duration

Period

More charts

Company Profile

Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 TissueNext tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.

Sector

Biotechnology & Medical Research

Calendar

2024-05-01 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Guardant Health, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

16.39 USD

Average target price

40.12 USD

Spread / Average Target

+144.81%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
GUARDANT HEALTH, INC.	-39.41%	1.99B
EXACT SCIENCES CORPORATION	-14.54%	11.48B
IOVANCE BIOTHERAPEUTICS, INC.	+45.14%	3.3B
BGI GENOMICS CO., LTD.	-19.98%	2.01B
VERACYTE, INC.	-31.44%	1.42B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+18.02%	1.02B
SEEGENE, INC.	-8.30%	699M
CAREDX, INC	-31.00%	429M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-50.20%	354M
CURIOX BIOSYSTEMS CO., LTD	-11.23%	259M

Bio Diagnostics & Testing